Cargando…

Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study

Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Binbin, Liu, Longshan, Liu, Xiaoman, Huang, Min, Chen, Xiao, Tang, Kejing, Wang, Changxi, Chen, Pan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040645/
https://www.ncbi.nlm.nih.gov/pubmed/36992828
http://dx.doi.org/10.3389/fphar.2023.1126765
_version_ 1784912522323689472
author Lv, Binbin
Liu, Longshan
Liu, Xiaoman
Huang, Min
Chen, Xiao
Tang, Kejing
Wang, Changxi
Chen, Pan
author_facet Lv, Binbin
Liu, Longshan
Liu, Xiaoman
Huang, Min
Chen, Xiao
Tang, Kejing
Wang, Changxi
Chen, Pan
author_sort Lv, Binbin
collection PubMed
description Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to explore risk factors. The incidence of tac-DILI was 8.9% (95% CI = 7.2–10.7%). The most common type was cholestatic pattern (6.7%, 95% CI = 5.2–8.3%), followed by hepatocellular (1.6%, 95% CI = 0.8–2.4%) and mixed patterns (0.6%, 95% CI = 0.1–1.1%). 98.9% of recipients with tac-DILI have mild severity. The latency period were 42.0 (range, 21.5–99.8 days), 14.0 (range, 9.0–80.3 days), 16.0 (range, 11.5–24.5 days), and 49.0 days (range, 28.0–105.6 days) for total, hepatocellular, mixed, and cholestatic patterns, respectively. Baseline ALP level (OR = 1.015, 95% CI = 1.006–1.025, p = 0.002), age (OR = 0.971, 95% CI = 0.949–0.994, p = 0.006), and body weight (OR = 0.960, 95% CI = 0.940–0.982, p < 0.001) were independent risk factors. In conclusion, cholestatic pattern represents the most frequent type of tac-DILI. Young age, low body weight and abnormal baseline ALP level were risk factors.
format Online
Article
Text
id pubmed-10040645
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100406452023-03-28 Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study Lv, Binbin Liu, Longshan Liu, Xiaoman Huang, Min Chen, Xiao Tang, Kejing Wang, Changxi Chen, Pan Front Pharmacol Pharmacology Rare data reported tacrolimus-induced liver injury (tac-DILI) in real world. We performed a nested case-control analysis of 1,010 renal transplant recipients. Recipients with tac-DILI were randomly matched at a ratio of 1:4 by the year of admission to the remaining recipients without tac-DILI to explore risk factors. The incidence of tac-DILI was 8.9% (95% CI = 7.2–10.7%). The most common type was cholestatic pattern (6.7%, 95% CI = 5.2–8.3%), followed by hepatocellular (1.6%, 95% CI = 0.8–2.4%) and mixed patterns (0.6%, 95% CI = 0.1–1.1%). 98.9% of recipients with tac-DILI have mild severity. The latency period were 42.0 (range, 21.5–99.8 days), 14.0 (range, 9.0–80.3 days), 16.0 (range, 11.5–24.5 days), and 49.0 days (range, 28.0–105.6 days) for total, hepatocellular, mixed, and cholestatic patterns, respectively. Baseline ALP level (OR = 1.015, 95% CI = 1.006–1.025, p = 0.002), age (OR = 0.971, 95% CI = 0.949–0.994, p = 0.006), and body weight (OR = 0.960, 95% CI = 0.940–0.982, p < 0.001) were independent risk factors. In conclusion, cholestatic pattern represents the most frequent type of tac-DILI. Young age, low body weight and abnormal baseline ALP level were risk factors. Frontiers Media S.A. 2023-03-13 /pmc/articles/PMC10040645/ /pubmed/36992828 http://dx.doi.org/10.3389/fphar.2023.1126765 Text en Copyright © 2023 Lv, Liu, Liu, Huang, Chen, Tang, Wang and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lv, Binbin
Liu, Longshan
Liu, Xiaoman
Huang, Min
Chen, Xiao
Tang, Kejing
Wang, Changxi
Chen, Pan
Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
title Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
title_full Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
title_fullStr Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
title_full_unstemmed Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
title_short Incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: A nested case-control study
title_sort incidence, clinical features and risk factors of tacrolimus induced idiosyncratic liver injury in renal transplant recipients: a nested case-control study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040645/
https://www.ncbi.nlm.nih.gov/pubmed/36992828
http://dx.doi.org/10.3389/fphar.2023.1126765
work_keys_str_mv AT lvbinbin incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy
AT liulongshan incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy
AT liuxiaoman incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy
AT huangmin incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy
AT chenxiao incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy
AT tangkejing incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy
AT wangchangxi incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy
AT chenpan incidenceclinicalfeaturesandriskfactorsoftacrolimusinducedidiosyncraticliverinjuryinrenaltransplantrecipientsanestedcasecontrolstudy